Status and phase
Conditions
Treatments
About
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
Full description
This is an open-label, multicenter, Phase 1 clinical trial to evaluate the maximum tolerated dose, safety, pharmacokinetic/pharmacodynamic characteristics and preliminary anti-tumor activity of SB17170 when administered alone(1a) and co-administered with standard of care(1b) to patients with locally advanced or metastatic solid tumors who have failed standard of care.
1 cycle of treatment of this clinical trial is 21 days, and tumors are assessed every 2 cycles.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
50 participants in 5 patient groups
Loading...
Central trial contact
Yongmi Yu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal